Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas such ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.

BLUETTI, a leading global provider of clean energy solutions, unveils the ES125 C&I energy storage system, delivering a ...

Background The epidemiology and long-term healthcare utilisation associated with chronic kidney disease (CKD) among those ...

Bristol Myers Squibb hasn’t had much luck with its efforts to develop cancer treatments called T cell engagers. But the pharmaceutical company isn’t done pursuing this type of targeted cancer therapy, ...

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...

Bristol Myers Squibb (BMS) has agreed as part of a deal with the US government to provide Eliquis (apixaban) free of charge to Medicaid. The company has also agreed to donate more than seven tons of ...

Sometimes it takes a combination of building pressures to spark a landslide of positive change. For pharmaceutical giant Bristol Myers Squibb (BMS), the moment came following its $74 billion ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Fenton-based UniGroup has ...

BMS is focusing on a diversified portfolio to stabilize and grow revenues post-loss-of-exclusivity, avoiding reliance on a single blockbuster. Pipeline execution in oncology, cardiovascular, and ...